Bilcare Limited has informed the Exchange about that Exercise of Right of Conversion of Convertible Warrants
BI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bilcare's board, at its February 12, 2026 meeting, approved unaudited standalone and consolidated financial results for Q3 and 9M FY26 (ended December 31, 2025). Standalone Q3 showed a net profit of Rs.2.71 crore on revenue of Rs.1.73 crore, while consolidated Q3 posted a net loss of Rs.12.81 crore on revenue of Rs.181.32 crore. For 9M FY26, standalone net profit was Rs.1.04 crore versus a consolidated net loss of Rs.16.28 crore. Two capital actions were announced: Caprihans India Limited (CIL, a subsidiary) will redeem 2.80 crore preference shares held by Bilcare by March 31, 2026, and Bilcare will convert 18.70 lakh convertible warrants (out of 33.10 lakh outstanding) issued by CIL into equity shares by paying Rs.28.05 crore. The statutory auditor issued a qualified review conclusion, flagging that Rs.14.42 crore CSIR loan penal interest should have been a provision rather than a contingent liability, and noting material uncertainty about the company's ability to continue as a going concern due to past operating losses.
The auditor's qualified review, going-concern uncertainty, and consolidated losses (Rs.16.28 crore for 9M FY26) are significant red flags that may pressure the stock. The warrant conversion signals continued capital infusion into subsidiary Caprihans India, while preference share redemption provides liquidity to Bilcare but reduces its passive investment income.